Cocrystal Pharma doses first subjects in study of CDI-988

Cocrystal Pharma, announces dosing of the first subjects in a Phase 1 clinical trial with its oral, first-in-class pan-norovirus and pan-coronavirus 3CL protease inhibitor CDI-988. “CDI-988 is a breakthrough discovery of the first-in-class pan-coronavirus and pan-norovirus antiviral agent with potential efficacy in these two indications and we excited to take the first step in its clinical development. Our oral antiviral candidate has the potential to save patient lives and reduce the severity of norovirus and coronavirus infections now and in future pandemic outbreaks,” said Sam Lee, Ph.D., Cocrystal’s President and co-CEO. “We are looking forward to advancing CDI-988 to the next stage of norovirus and coronavirus clinical development upon completion of this Phase 1 study, setting up a transformational year ahead for Cocrystal.”